{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T06:32:07Z","timestamp":1721543527736},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.medcli.2014.12.025","type":"journal-article","created":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T11:50:55Z","timestamp":1428493855000},"page":"74-80","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Reca\u00edda en el sistema nervioso central en el linfoma B difuso de c\u00e9lula grande: factores de riesgo"],"prefix":"10.1016","volume":"146","author":[{"given":"Juan-Manuel","family":"Sancho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep-Maria","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2014.12.025_bib0235","unstructured":"L\u00f3pez-Guillermo A, Bosch-Albareda F. Linfomas y otras enfermedades ganglionares. En: Farreras-Rozman Medicina Interna. 17.a ed. Barcelona: Elsevier; 2012. p. 1601-1619."},{"key":"10.1016\/j.medcli.2014.12.025_bib0240","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"Shipp","year":"1993","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2014.12.025_bib0245","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2014.12.025_bib0250","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomized study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0255","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0260","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1055\/s-2004-861534","article-title":"Prevention and treatment of central nervous system involvement by non-Hodgkin's lymphoma: A review of the literature","volume":"24","author":"Colocci","year":"2004","journal-title":"Semin Neurol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0265","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2005.01.131","article-title":"Neoplastic meningitis","volume":"23","author":"Chamberlain","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0270","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1157\/13126952","article-title":"Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin's lymphoma in Spain","volume":"131","author":"Sancho","year":"2008","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.medcli.2014.12.025_bib0275","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/annonc\/mdh013","article-title":"Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: Influence of rituximab","volume":"15","author":"Feugier","year":"2004","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0280","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood-2008-10-182253","article-title":"CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: An analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"113","author":"Boehme","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2014.12.025_bib0285","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/annonc\/mdp432","article-title":"Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: The impact of the addition of rituximab to CHOP chemotherapy","volume":"21","author":"Villa","year":"2010","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0290","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1600-0609.2010.01478.x","article-title":"Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era","volume":"85","author":"Sancho","year":"2010","journal-title":"Eur J Haematol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0295","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s12185-009-0289-2","article-title":"Diffuse large B-cell lymphoma with central nervous system relapse: Prognosis and risk factors according to retrospective analysis from a single-center experience","volume":"89","author":"Shimazu","year":"2009","journal-title":"Int J Hematol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0300","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2141.2011.08998.x","article-title":"The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma","volume":"157","author":"Mitrovic","year":"2012","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0305","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/annonc\/mdr440","article-title":"CNS disease in younger patients with aggressive B-cell lymphoma: An analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"23","author":"Schmitz","year":"2012","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0310","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3324\/haematol.2013.101741","article-title":"Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma","volume":"99","author":"Wilson","year":"2014","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2014.12.025_bib0315","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2012.09247.x","article-title":"Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: A single centre experience and review of the literature","volume":"159","author":"Guirguis","year":"2012","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0320","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3892\/ol.2012.755","article-title":"Central nervous system involvement in adult patients with diffuse large B-cell lymphoma: Influence of rituximab","volume":"4","author":"Cao","year":"2012","journal-title":"Oncol Lett."},{"key":"10.1016\/j.medcli.2014.12.025_bib0325","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1002\/cncr.26588","article-title":"Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: Findings from a large national database","volume":"118","author":"Kumar","year":"2012","journal-title":"Cancer."},{"key":"10.1016\/j.medcli.2014.12.025_bib0330","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12185-013-1458-x","article-title":"Secondary central nervous system involvement in 599 patients with diffuse large B-cell lymphoma: Are there any changes in the rituximab era?","volume":"98","author":"Deng","year":"2013","journal-title":"Int J Hematol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0335","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1600-0609.2010.01438.x","article-title":"Central nervous system involvement in diffuse large B cell lymphoma","volume":"85","author":"Yamamoto","year":"2010","journal-title":"Eur J Haematol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0340","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00277-010-1150-7","article-title":"Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): Pre- and post-rituximab","volume":"90","author":"Tai","year":"2011","journal-title":"Ann Hematol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0345","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3109\/10428194.2011.596966","article-title":"Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: Analyses with competing risk regression model","volume":"52","author":"Chihara","year":"2011","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.medcli.2014.12.025_bib0350","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/10428194.2013.811239","article-title":"Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: A systematic review and meta-analysis","volume":"55","author":"Zhang","year":"2014","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.medcli.2014.12.025_bib0355","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bjh.12509","article-title":"Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology","volume":"163","author":"McMillan","year":"2013","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0360","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood.V91.4.1178","article-title":"Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma","volume":"91","author":"Van Besien","year":"1998","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2014.12.025_bib0365","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1023\/A:1008394827806","article-title":"Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients","volume":"11","author":"Haioun","year":"2000","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0370","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/annonc\/mdf175","article-title":"Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: A risk model","volume":"13","author":"Hollender","year":"2002","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0375","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/annonc\/mdl327","article-title":"Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--A survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)","volume":"18","author":"Boehme","year":"2007","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0465","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1349-7006.2011.02139.x","article-title":"Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era","volume":"103","author":"Tomita","year":"2012","journal-title":"Cancer Sci."},{"key":"10.1016\/j.medcli.2014.12.025_bib0470","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2008.16.8021","article-title":"Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: A 20-year follow-up analysis of SWOG 8516--The Southwest Oncology Group","volume":"27","author":"Bernstein","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0475","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.3109\/10428194.2013.869326","article-title":"Central nervous system involvement in diffuse large B-cell lymphoma: An analysis of risks and prevention strategies in the post-rituximab era","volume":"55","author":"Fletcher","year":"2014","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.medcli.2014.12.025_bib0480","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/1097-0142(19820201)49:3<586::AID-CNCR2820490331>3.0.CO;2-C","article-title":"Central nervous system involvement in non-Hodgkin's lymphoma: An analysis of 105 cases","volume":"49","author":"MacKintosh","year":"1982","journal-title":"Cancer."},{"key":"10.1016\/j.medcli.2014.12.025_bib0485","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/hon.2900080305","article-title":"Secondary central nervous system involvement by non-Hodgkin's lymphoma: The risk factors","volume":"8","author":"Liang","year":"1990","journal-title":"Hematol Oncol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0490","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2003.11.141","article-title":"Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group","volume":"21","author":"Zucca","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0495","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1080\/02841860410002851","article-title":"Testicular lymphoma--A retrospective, population-based, clinical and immunohistochemical study","volume":"43","author":"Hasselblom","year":"2004","journal-title":"Acta Oncol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0500","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1080\/1042819031000079195","article-title":"Primary breast lymphoma","volume":"44","author":"Gholam","year":"2003","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.medcli.2014.12.025_bib0420","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ijc.26352","article-title":"Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy","volume":"131","author":"Yhim","year":"2012","journal-title":"Int J Cancer."},{"key":"10.1016\/j.medcli.2014.12.025_bib0425","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bjh.12753","article-title":"A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era","volume":"165","author":"Hosein","year":"2014","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0430","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3324\/haematol.2011.041277","article-title":"Diffuse large B-cell lymphoma with involvement of the kidney: Outcome and risk of central nervous system relapse","volume":"96","author":"Villa","year":"2011","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2014.12.025_bib0435","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00277-008-0682-6","article-title":"Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement","volume":"88","author":"Lee","year":"2009","journal-title":"Ann Hematol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0440","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood-2013-10-535021","article-title":"The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas","volume":"124","author":"Murawski","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2014.12.025_bib0445","first-page":"1","author":"Lee","year":"2014","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.medcli.2014.12.025_bib0450","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/leu.2008.344","article-title":"Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8 q24\/c-MYC translocations","volume":"23","author":"Niitsu","year":"2009","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2014.12.025_bib0455","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/PAS.0b013e3181cd3aeb","article-title":"B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma","volume":"34","author":"Snuderl","year":"2010","journal-title":"Am J Surg Pathol."},{"key":"10.1016\/j.medcli.2014.12.025_bib0460","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3324\/haematol.2008.005355","article-title":"Clinicopathological features of lymphoma\/leukemia patients carrying both BCL2 and MYC translocations","volume":"94","author":"Tomita","year":"2009","journal-title":"Haematologica."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775315000755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775315000755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T08:01:39Z","timestamp":1717833699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775315000755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0025775315000755"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2014.12.025","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reca\u00edda en el sistema nervioso central en el linfoma B difuso de c\u00e9lula grande: factores de riesgo","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2014.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}